Time-Dependent Clinical and Laboratory Variables
| Variable . | Autologous PBSC (n = 355) . | Allogeneic BM (n = 283) . | ||
|---|---|---|---|---|
| Eval . | n (%) . | No. Pts. . | n (%) . | |
| PBSC boost | 355 | 3 (<1) | ||
| Posttransplant growth factors | 355 | 275 | ||
| Begun any time | 316 (89) | 133 (48) | ||
| Begun day 0-7 | 313 (88) | 77 (28) | ||
| GVHD prophylaxis | ||||
| Steroids | 275 | 111 (40) | ||
| Methotrexate | 275 | 231 (84) | ||
| Gancyclovir use | 275 | 114 (42) | ||
| GVHD (grade II-IV) | 268 | 102 (38) | ||
| Posttransplant clinical events | ||||
| Neutrophil recovery* | 354 | 330 (93) | 273 | 241 (88) |
| Fever 38-39°C | 355 | 143 (40) | 275 | 113 (41) |
| Fever >39°C | 355 | 161 (45) | 275 | 105 (38) |
| Veno-occlusive disease | 355 | 9 (3) | 275 | 57 (21) |
| DIC | 355 | 3 (<1) | 275 | 4 (2) |
| TMA | 355 | 1 (<1) | 275 | 6 (2) |
| Death | 329 | 14 (4) | 279 | 47 (17) |
| Variable . | Autologous PBSC (n = 355) . | Allogeneic BM (n = 283) . | ||
|---|---|---|---|---|
| Eval . | n (%) . | No. Pts. . | n (%) . | |
| PBSC boost | 355 | 3 (<1) | ||
| Posttransplant growth factors | 355 | 275 | ||
| Begun any time | 316 (89) | 133 (48) | ||
| Begun day 0-7 | 313 (88) | 77 (28) | ||
| GVHD prophylaxis | ||||
| Steroids | 275 | 111 (40) | ||
| Methotrexate | 275 | 231 (84) | ||
| Gancyclovir use | 275 | 114 (42) | ||
| GVHD (grade II-IV) | 268 | 102 (38) | ||
| Posttransplant clinical events | ||||
| Neutrophil recovery* | 354 | 330 (93) | 273 | 241 (88) |
| Fever 38-39°C | 355 | 143 (40) | 275 | 113 (41) |
| Fever >39°C | 355 | 161 (45) | 275 | 105 (38) |
| Veno-occlusive disease | 355 | 9 (3) | 275 | 57 (21) |
| DIC | 355 | 3 (<1) | 275 | 4 (2) |
| TMA | 355 | 1 (<1) | 275 | 6 (2) |
| Death | 329 | 14 (4) | 279 | 47 (17) |
Abbreviations: Eval, number of patients for which data are available; n, number of patients for which that variable pertains; PBSC boost defined as additional PBSC infusion given >3 days after initial cell infusion; GVHD, graft-versus-host disease; Temp, temperature; DIC, disseminated intravascular coagulation; TMA, thrombotic microangiopathy (thrombotic thrombocytopenia purpura and hemolytic uremia syndrome).
Patients who died or were lost to follow-up before achieving neutrophil recovery were considered not to have recovered. Fever is the maximum temperature reported during the first 15 days after transplant.